検索
Biogen Inc
BIIBウォッチリストに追加
202.190USD
+1.570+0.78%
終値 07-24 16:00（ET）15分遅れの株価
29.84B時価総額
21.63直近12ヶ月PER
詳細情報 Biogen Inc 企業名
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Incの企業情報
企業コードBIIB
会社名Biogen Inc
上場日Sep 17, 1991
最高経営責任者「CEO」Viehbacher (Christopher A)
従業員数7605
証券種類Ordinary Share
決算期末Sep 17
本社所在地225 Binney Street
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02142
電話番号17814642000
ウェブサイトhttps://www.biogen.com/
企業コードBIIB
上場日Sep 17, 1991
最高経営責任者「CEO」Viehbacher (Christopher A)
Biogen Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.89K
+16.92%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.04K
-0.01%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
6.45K
+31.09%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
6.37K
+7.60%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
よくある質問
Biogen Incの上位5名の株主は誰ですか？
Biogen Incの上位5名の株主は以下のとおりです。Ms. Susan H. Alexander, Esq., J.D.
Biogen Inc（BIIB）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Biogen Incの株式を保有している機関は2085社あり、保有株式の総市場価値は約144.76Mで、全体の98.05%を占めています。2025Q4と比較して、機関の持ち株は-3983853.00増加しています。
Biogen Incの最大の収益源は何ですか？
2026Q1において、Spinal Muscular Atrophy-SPINRAZA部門がBiogen Incにとって最大の収益を生み出しており、その金額は2.15Bで、全収益の21.78%を占めています。